Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.36 |
| ▸ | FNTB | P49356 | 10/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16160947 | 1.00 | FNTA (0.36) | FNTAFNTBKCNH2PGGT1BMMP1 | |
| SCHEMBL16160938 | 1.00 | FNTA (0.36) | FNTAFNTBKCNH2PGGT1BMMP1 | |
| SCHEMBL16160926 | 0.96 | FNTA (0.39) | FNTAFNTBKCNH2PGGT1B | |
| SCHEMBL16160924 | 0.95 | WDR5 (0.36) | FNTAFNTBKCNH2PGGT1BWDR5 | |
| SCHEMBL16160955 | 0.94 | FNTA (0.35) | FNTAFNTBKCNH2PGGT1B | |
| SCHEMBL16160940 | 0.94 | FNTA (0.35) | FNTAFNTBKCNH2PGGT1B | |
| SCHEMBL16160956 | 0.94 | FNTA (0.35) | FNTAFNTBKCNH2PGGT1B | |
| SCHEMBL16160936 | 0.93 | CTSL (0.36) | FNTAFNTBKCNH2MMP1 | |
| SCHEMBL16160953 | 0.93 | CTSL (0.36) | FNTAFNTBKCNH2MMP1 | |
| SCHEMBL16160939 | 0.93 | CTSL (0.36) | FNTAFNTBKCNH2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150527-B2 | Metalloenzyme inhibitor compounds | INNOCRIN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | FNTA 1764/4885FNTB 1177/4885KCNH2 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.